Quantcast

Latest Glutathione Stories

2011-06-07 15:05:00

PALO ALTO, Calif., June 7, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome (del 5q MDS). This is a multicenter trial intended to enroll up to 117 evaluable patients. It employs a sequential design with two interim analyses. These patients are transfusion dependent with Low to Intermediate-1 Risk MDS. Telintra will be...

2011-06-03 12:16:30

Two promising new treatments to aid people with autism have shown effectiveness in pilot studies conducted by an Arizona State University professor and private researchers. Several studies indicate that children with autism often have abnormalities in critical biochemical functions that help maintain health "“ specifically methylation, glutathione, and mitochondrial functions. Methylation turns proteins in the body on and off "“ including DNA and RNA "“ a function that...

2011-06-03 07:30:00

SAN DIEGO, June 3, 2011 /PRNewswire/ -- LifeVantage Corporation (OTCBB: LFVN), the maker of Protandim®, a clinically demonstrated, science-based therapy for the reduction of oxidative stress by the synergistic activation of Nrf2, announced today that a new peer-reviewed review article involving Protandim® was published in the scientific journal Enzyme Research. (Logo: http://photos.prnewswire.com/prnh/20090930/LIFEVANTAGELOGO) The review,...

2011-04-05 07:00:00

PALO ALTO, Calif., April 5, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today presented data at the 102nd American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida on a group of second generation analogs of ezatiostat, the most clinically advanced product in development at Telik. Ezatiostat is the first inhibitor of glutathione-S-transferase P1-1 (GST P-1), a validated enzyme target in Myelodysplastic Syndrome (MDS), to successfully complete a Phase 2 clinical...

2011-03-30 15:05:00

PALO ALTO, Calif., March 30, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 10th Annual Needham Healthcare Conference in New York City on Wednesday, April 6 at 11:20 a.m. Eastern time (8:20 a.m. Pacific time), in the New York Palace Hotel's Henry's Suite. A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of the...

2011-03-25 18:31:00

PALO ALTO, Calif., March 25, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced that a presentation titled: "Synthesis and biochemical characterization of novel analogues of ezatiostat hydrochloride (TLK199, Telintra®)" will be given at the 102nd annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida. The presentation will be made on Tuesday, April 5th, 2011 from 8:00 am - 12:00 pm in Exhibit Hall A4-C, Poster Section; Cancer...

2011-02-22 15:30:00

PALO ALTO, Calif., Feb. 22, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) reported a net loss of $9.8 million, or $0.18 per share, for the three months ended December 31, 2010, compared with a net loss of $4.2 million, or $0.08 per share, for the comparable period in 2009. For the year ended December 31, 2010, net loss was $24.7 million, or $0.46 per share, compared with a net loss of $23.7 million, or $0.44 per share, for the year ended December 31, 2009. For the quarter ended December...

2011-02-09 03:25:00

PALO ALTO, Calif., Feb. 9, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 13th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 15 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time), in the Waldorf-Astoria Hotel's Conrad Suite. A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of the...

2011-01-04 07:00:00

SAN DIEGO, Jan. 4, 2011 /PRNewswire/ -- LifeVantage Corporation (OTC Bulletin Board: LFVN), the maker of science-based solutions to oxidative stress, announced today that a new peer-reviewed study involving its flagship product, Protandim®, sponsored by the American Heart Association and the National Institutes of Health, was published in the scientific journal Free Radical Biology and Medicine. The study, conducted by researchers at The Ohio State University, examined...

2010-12-07 06:00:00

BEVERLY HILLS, Calif., Dec. 7, 2010 /PRNewswire/ -- OXIS International, Inc. (OTC Bulletin Board: OXIS; Euronext Paris: OXI) announces the market launch of ErgoFlex(TM), a unique new dietary supplement for the relief of joint pain. It is the first in a series of commercial products planned by OXIS. ErgoFlex is the only joint health complex containing the powerful antioxidant Ergothioneine (ERGO), and is specifically formulated to help the body fight the pain of joint inflammation and...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.